UK-based oncology developer Biosceptre raised £8m ($10.7m) in a series A round on Thursday led by Tuspark Science and Technology Service, a venture capital subsidiary of Tsinghua University.
Tuspark took part through its Bluesky Partnership II fund, however further details were not disclosed. Biosceptre expects to close the round on December 21.
Biosceptre is working on therapies that target nfP2X7, a mutated ion channel it claims is present on diseased cells in more than 20 forms of cancer.
The cash…
